Targeting the ATR-CHK1 Axis in Cancer Therapy. (2017)
Attributed to:
Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cancers9050041
PubMed Identifier: 28448462
Publication URI: http://europepmc.org/abstract/MED/28448462
Type: Journal Article/Review
Volume: 9
Parent Publication: Cancers
Issue: 5
ISSN: 2072-6694